JP7612682B2 - 新規なテトラゾール - Google Patents

新規なテトラゾール Download PDF

Info

Publication number
JP7612682B2
JP7612682B2 JP2022522022A JP2022522022A JP7612682B2 JP 7612682 B2 JP7612682 B2 JP 7612682B2 JP 2022522022 A JP2022522022 A JP 2022522022A JP 2022522022 A JP2022522022 A JP 2022522022A JP 7612682 B2 JP7612682 B2 JP 7612682B2
Authority
JP
Japan
Prior art keywords
diseases
trpa1
compounds
compound
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022522022A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022552520A5 (OSRAM
JP2022552520A (ja
Inventor
マルティン トーマス フレック
フロリアン パウル クリスティアン ビンダー
ゲオルク ダーマン
イェルク ピー ヘーン
ウータ フリーデリーケ レッセル
イェンス ヴィルヴァチャー
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2022552520A publication Critical patent/JP2022552520A/ja
Publication of JP2022552520A5 publication Critical patent/JP2022552520A5/ja
Application granted granted Critical
Publication of JP7612682B2 publication Critical patent/JP7612682B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2022522022A 2019-10-15 2020-10-14 新規なテトラゾール Active JP7612682B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19203174 2019-10-15
EP19203174.8 2019-10-15
PCT/EP2020/078856 WO2021074198A1 (en) 2019-10-15 2020-10-14 Novel tetrazoles

Publications (3)

Publication Number Publication Date
JP2022552520A JP2022552520A (ja) 2022-12-16
JP2022552520A5 JP2022552520A5 (OSRAM) 2023-10-24
JP7612682B2 true JP7612682B2 (ja) 2025-01-14

Family

ID=68289875

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022522022A Active JP7612682B2 (ja) 2019-10-15 2020-10-14 新規なテトラゾール

Country Status (5)

Country Link
US (1) US12497401B2 (OSRAM)
EP (1) EP4045053B1 (OSRAM)
JP (1) JP7612682B2 (OSRAM)
CN (1) CN114555601B (OSRAM)
WO (1) WO2021074198A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114555601B (zh) * 2019-10-15 2024-04-02 勃林格殷格翰国际有限公司 新颖的四唑类
AU2022257269A1 (en) 2021-04-14 2023-08-17 Boehringer Ingelheim International Gmbh 3H,4H-THIENO[2,3-d]PYRIMIDIN-4-ONE DERIVATIVES AS TRPA1 INHIBITORS
IT202100015098A1 (it) 2021-06-09 2022-12-09 Flonext S R L Composto antagonista del canale trpa1 per uso in patologie degenerative della retina
WO2025167992A1 (zh) * 2024-02-08 2025-08-14 宜昌人福药业有限责任公司 一种非选择性阳离子通道trpa1拮抗剂及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015155306A1 (en) 2014-04-11 2015-10-15 Almirall, S.A. New trpa1 antagonists
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040256A1 (en) 1995-06-07 1996-12-19 G.D. Searle & Co. Method to treat cardiofibrosis with a combination of an angiotensin ii antagonist and spironolactone
US7754709B2 (en) 2003-06-10 2010-07-13 Solvay Pharmaceuticals Bv Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds
SG174398A1 (en) 2009-03-23 2011-10-28 Glenmark Pharmaceuticals Sa Furopyrimidinedione derivatives as trpa1 modulators
EP2655377B1 (en) 2010-12-20 2016-03-30 Glenmark Pharmaceuticals S.A. 2-amino-4-arylthiazole compounds as trpa1 antagonists
WO2012172475A1 (en) 2011-06-13 2012-12-20 Glenmark Pharmaceuticals S.A. Treatment of respiratory disorders using trpa1 antagonists
WO2016023832A1 (en) 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Thieno- and furo[2,3-d]pyrimidine-2,4[1h,3h]-dione derivatives as trpc5 modulators for the treatment of neuropsychiatric disorders
WO2016081649A1 (en) 2014-11-18 2016-05-26 Emory University Thieno[2,3-d]pyrimidin-4-one derivatives as nmdar modulators and uses related thereto
WO2016133888A1 (en) 2015-02-16 2016-08-25 Biota Pharmaceuticals, Inc. Compounds for treating respiratory syncytial virus infections
EP3655409B1 (en) 2017-07-17 2023-12-27 Nanjing Ruijie Pharmatech Co., Ltd. Novel compounds and their uses as acc inhibitors
CN114555601B (zh) * 2019-10-15 2024-04-02 勃林格殷格翰国际有限公司 新颖的四唑类
CN114945408B (zh) 2019-10-15 2024-04-16 勃林格殷格翰国际有限公司 作为trpa1抑制剂的噻吩并嘧啶酮
BR112022003862A2 (pt) 2019-10-15 2022-08-23 Boehringer Ingelheim Int Tienopirimidonas como inibidores de trpa1
DK4228755T3 (da) 2020-10-14 2025-02-03 Boehringer Ingelheim Int Tetrazol-derivater som trpa1-hæmmere
CA3193606A1 (en) 2020-10-14 2022-04-21 Boehringer Ingelheim International Gmbh Tetrazole derivatives as trpa1 inhibitors
AU2022257269A1 (en) 2021-04-14 2023-08-17 Boehringer Ingelheim International Gmbh 3H,4H-THIENO[2,3-d]PYRIMIDIN-4-ONE DERIVATIVES AS TRPA1 INHIBITORS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015155306A1 (en) 2014-04-11 2015-10-15 Almirall, S.A. New trpa1 antagonists
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Schenkel L.B. et al.，J. Med. Chem.，2016年，59，p.2794-2809

Also Published As

Publication number Publication date
US12497401B2 (en) 2025-12-16
JP2022552520A (ja) 2022-12-16
US20240101561A1 (en) 2024-03-28
CN114555601A (zh) 2022-05-27
CN114555601B (zh) 2024-04-02
EP4045053B1 (en) 2023-12-06
EP4045053A1 (en) 2022-08-24
WO2021074198A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
JP7627782B2 (ja) Ｔｒｐａ１阻害剤としての、３ｈ，４ｈ，５ｈ，６ｈ，７ｈ－ピリミド［４，５－ｂ］［１，４］オキサジン－４，６－ジオン誘導体
JP7376706B2 (ja) Ｔｒｐａ１阻害剤としてのチエノピリミドン
JP7565439B2 (ja) Ｔｒｐａ１阻害剤としてのテトラゾール誘導体
JP7617306B2 (ja) Ｔｒｐａ１阻害剤としてのウラシル誘導体
JP7354438B2 (ja) Ｔｒｐａ１阻害剤としてのチエノピリミドン
CN114555601B (zh) 新颖的四唑类
JP7565457B2 (ja) ＴＲＰＡ１阻害剤としての３Ｈ，４Ｈ－チエノ－［２，３－ｄ］ピリミジン－４－オン誘導体
JP7565440B2 (ja) Ｔｒｐａ１阻害剤としてのテトラゾール誘導体
JP7602061B2 (ja) ＴＲＰＡ１阻害剤としてのイミダゾ［４，５－ｄ］ピリダジノニル誘導体
JP7539500B2 (ja) Ｔｒｐａ１阻害剤としてのテトラゾール誘導体
JP7539501B2 (ja) Ｔｒｐａ１阻害剤としてのテトラゾール誘導体
EA047941B1 (ru) Производные урацила в качестве ингибиторов trpa1
EA047979B1 (ru) ПРОИЗВОДНЫЕ 3Н,4Н-ТИЕНО[2,3-d]ПИРИМИДИН-4-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ TRPA1
EA047912B1 (ru) ПРОИЗВОДНЫЕ 3Н,4Н,5Н,6Н,7Н-ПИРИМИДО[4,5-b][1,4]ОКСАЗИН-4,6-ДИОНА В КАЧЕСТВЕ ИНГИБИТОРОВ TRPA1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231013

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231013

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241125

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241225

R150 Certificate of patent or registration of utility model

Ref document number: 7612682

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150